Research programme: phosphodiesterase V inhibitors - Plexxikon

Next Previous
Drug Profile

Research programme: phosphodiesterase V inhibitors - Plexxikon

Alternative Names: Phosphodiesterase V inhibitors research programme - Plexxikon

Latest Information Update: 10 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Plexxikon
  • Class
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Erectile dysfunction

Most Recent Events

  • 10 Mar 2008 No development reported - Preclinical for Erectile dysfunction in USA (unspecified route)
  • 27 Feb 2004 Compounds from this programme are available for licensing (http://www.plexxikon.com/)
  • 27 Feb 2004 Preclinical trials in Erectile dysfunction in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top